Erratum to: Symptomatic and Palliative Care for Stroke SurvivorsClaire J. Creutzfeldt, MD1, Robert G. Holloway, MD, MPH2,3, and Melanie Walker, MD1

1Department of Neurology, University of Washington Harborview Medical Center, Seattle, WA, USA; 2Department of Neurology, University ofRochester Medical Center, Rochester, NY, USA; 3Department of Medicine, Division of Pallative Care, University of Rochester Medical Center,Rochester, NY, USA.

J Gen Intern Med

DOI: 10.1007/s11606-014-2876-z

© Society of General Internal Medicine 2014

Erratum to: J Gen Intern MedDOI: 10.1007/s11606-011-1966-4

On page 857 of the original publication, the followingstatement contains a technical error.

Recently, the FDA approved Nuedexta, a fixed-dosecombination of the cough suppressant dextromethorphanhydrobromide and the antiarrhythmic quinidine sulfate, fortreatment of pseudobulbar affect in patients with amyotro-phic lateral sclerosis or multiple sclerosis.

Correction: Although the FDA approved Nuedexta basedon studies in AML and MS, the approved indication was fortreatment of pseudobulbar palsy (without restriction to aspecific underlying condition).

The online version of the original article can be found at http://dx.doi.org/10.1007/s11606-011-1966-4.